Gilead Sciences (NASDAQ:GILD) Given “Hold” Rating at Needham & Company LLC

Gilead Sciences (NASDAQ:GILD)‘s stock had its “hold” rating restated by Needham & Company LLC in a research note issued to investors on Friday,Benzinga reports.

Several other equities research analysts have also recently issued reports on GILD. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, March 27th. Bank of America boosted their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. BMO Capital Markets increased their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price objective on the stock. Finally, DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a report on Thursday, February 13th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $109.43.

Gilead Sciences Trading Down 2.8 %

Shares of GILD stock opened at $103.17 on Friday. Gilead Sciences has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The stock’s fifty day moving average is $109.21 and its two-hundred day moving average is $98.24. The firm has a market capitalization of $128.46 billion, a P/E ratio of 278.84, a PEG ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.73 by $0.08. The firm had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. During the same quarter last year, the firm earned ($1.32) earnings per share. Research analysts expect that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total value of $260,225.00. Following the transaction, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at $17,597,559.49. This trade represents a 1.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders sold 302,785 shares of company stock worth $30,540,875. 0.27% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Gilead Sciences

Several large investors have recently bought and sold shares of the stock. Westside Investment Management Inc. increased its position in Gilead Sciences by 3.5% during the third quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company’s stock worth $2,249,000 after buying an additional 917 shares during the period. SkyView Investment Advisors LLC grew its position in shares of Gilead Sciences by 5.4% during the third quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company’s stock worth $711,000 after acquiring an additional 435 shares during the last quarter. Pine Valley Investments Ltd Liability Co acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at $209,000. World Investment Advisors LLC raised its position in Gilead Sciences by 33.6% in the 3rd quarter. World Investment Advisors LLC now owns 25,999 shares of the biopharmaceutical company’s stock valued at $2,180,000 after purchasing an additional 6,535 shares during the last quarter. Finally, Arvest Bank Trust Division acquired a new stake in Gilead Sciences during the 3rd quarter worth $9,661,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.